Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.

Jorge E. Cortes,Michael J. Mauro,Michael W. Deininger,Charles Chuah,Dong-Wook Kim,Vamsi Kota,Jeffrey H. Lipton,Philippe Rousselot,Dragana Milojkovic,Phillipp D. Le Coutre,Valentín García Gutiérrez,Rocco J. Crescenzo,Eric Leip,Fiona An,Nathalie Bouxin,Andreas Hochhaus,Tim H. Brümmendorf,Carlo Gambacorti Passerini

Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.

2018

Jorge E. Cortes
Michael J. Mauro
Michael W. Deininger
Charles Chuah
Dong-Wook Kim
Vamsi Kota
Jeffrey H. Lipton
Philippe Rousselot
Dragana Milojkovic
Phillipp D. Le Coutre
Valentín García Gutiérrez
Rocco J. Crescenzo
Eric Leip
Fiona An
Nathalie Bouxin
Andreas Hochhaus
Tim H. Brümmendorf
Carlo Gambacorti Passerini

7002Background: Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) and CML resistant/intolerant to...

Keywords:

Bosutinib
Myeloid leukemia
Physical therapy
Imatinib
Medicine
newly diagnosed
ABL Tyrosine Kinase
Proto-oncogene tyrosine-protein kinase Src
Oncology
Internal medicine
month follow up
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations